Sarah Cannon Inks Personalized Medicine Pact with AstraZeneca | GenomeWeb

NEW YORK (GenomeWeb News) – Sarah Cannon Research Institute and AstraZeneca said today that they will work together to advance drugs in AstraZeneca's pipeline with a personalized medicine strategy.

The collaborators said they will analyze tissue samples from cancer patients to gauge biomarkers linked to treatment response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.